There are over 1 million hospitalizations for heart failure per year in North America, most of which are driven by fluid overload. The gold standard therapy for patients admitted with congestive heart failure is IV diuretics. However, the process of treating patients with IV diuretics is challenging, with 1 in 4 patients having their diuretics stopped prematurely and 1 in 3 patients being discharged with residual congestion – factors that lead to increased lengths of hospital stays, and higher readmission rates. Much of this challenge is due to the lack of adequate hemodynamic monitoring of congestion in patients admitted to hospital with heart failure, particularly on general medical or cardiology wards where invasive hemodynamic monitoring is not permitted. Venamic is an early-stage medical device company developing a novel non-invasive hemodynamic monitoring system for patients admitted to hospital with acute heart failure, particularly in non-critical care settings.